Advertisement
Management will provide a general corporate update and review of severalimportant milestones, including the recent FDA approval of the Company'sCardiac Cryoablation System for the treatment of atrial flutter and thecompletion of enrollment of the Company's pivotal clinical trial for atrialfibrillation. CryoCor began selling its Cryoablation System in the fourthquarter of 2007, and is initially targeting placements with thought-leadingelectrophysiologists in high-volume ablation centers across the U.S. CryoCoris the first company to complete enrollment of a pivotal clinical trial foratrial fibrillation.
Advertisement
A live Web cast and recording of the presentation will be available onlinefrom the investor relations page of the Company's corporate Web site athttp://www.cryocor.com. The recording will remain available on CryoCor's Website for at least 30 days following presentation.
About CryoCor
CryoCor is a medical technology company that has developed andmanufactures a disposable catheter system based on its proprietarycryoablation technology for the minimally invasive treatment of cardiacarrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System,or the Cryoablation System, is designed to treat cardiac arrhythmias throughthe use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue.The Cryoablation System has been approved in Europe for the treatment ofatrial fibrillation, and atrial flutter, the two most common and difficult totreat arrhythmias, since 2002. In the United States, CryoCor has completedenrollment in a pivotal trial to evaluate the safety and efficacy of theCryoablation System for the treatment of atrial fibrillation and theCryoablation System has been approved in the United States for the treatmentof right atrial flutter. For more information please visit the Company'swebsite at http://www.cryocor.com
Forward Looking Statements
The statements in this press release that are not descriptions ofhistorical facts are forward-looking statements that are subject to risks anduncertainties. The actual events or results may differ materially from thoseprojected in such forward-looking statements due to a number of factors andthe risks and uncertainties identified in the Company's filings with theSecurities and Exchange Commission. These forward-looking statements speakonly as of the date hereof. The Company expressly disclaims any intent orobligation to update any of these forward-looking statements.CryoCor, Inc. The Ruth Group Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors) Chief Financial Officer (646) 536-7030 / 7020 (858) 909-2200 [email protected] [email protected] [email protected] Jason Rando (media) (646) 536-7025 [email protected]
SOURCE CryoCor, Inc.
